Objectives Pancreatic endocrine tumors (PETs) share numerous features with
gastrointestinal neuroendocrine (carcinoid) tumors. Targets of novel therapeutic strategies …

Although therapeutically actionable molecular alterations are widely distributed across many
cancer types, only a handful of them show evidence of clinical utility and are recommended …

Background The effect of anti-epidermal growth factor receptor (EGFR) antibodies (mAb) in
metastatic colorectal cancer seems limited to KRAS wild-type (wt) tumours, but still a major …

Signalling pathways that emerge from EGFR activation are critical in colon cancer (CC)
biology. Its targeting with specific drugs has opened a new window in the treatment of this …

Background K-RAS wild type colorectal tumors show an improved response rate to anti-
EGFR monoclonal antibodies. Nevertheless 70% to 40% of these patients still does not …

Somatic genetic alterations provide the foundation for the evolution of human tumors as well
as significant opportunity for therapeutic intervention. This review will cover the growing list …

Introduction: Cetuximab is a chimeric mAb with avidity for the EGFR higher than that of the
natural ligands of the receptor. Preclinical studies showed that cetuximab demonstrated …

Background: We hypothesized that a serum proteomic profile predictive of survival benefit in
non–small cell lung cancer patients treated with epidermal growth factor receptor tyrosine …

Background: Mucoepidermoid carcinoma (MEC) shows differences in biological behaviour
depending mainly on its histological grade. High-grade tumours usually have an aggressive …

Background: Only 40–70% of metastatic colorectal cancers (mCRCs) with wild-type (WT)
KRAS oncogene respond to anti-epidermal growth factor receptor (anti-EGFR) antibody …